ReviewThe AAPS journal2013
Population pharmacokinetics of cyclosporine in transplant recipients.
Review in The AAPS journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Engineering human Gut-on-a-Chip culturomics for predictive pharmacomicrobiomics of first-pass metabolism.npj biomedical innovations · 2026Review
- Cyclosporine related adverse events in aplastic anemia patients treated with immunosuppressive therapy.Annals of hematology · 2026Article
- Population Pharmacokinetics Model of Cyclosporin A in Children and Young Adult Renal Transplant Patients: Focus on Haemoglobin Contribution to Exposure Variability.Pharmaceutics · 2026Article
- Inflammation Decreases Ciclosporin Metabolism in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.Journal of clinical pharmacology · 2025Observational
- Review
- Initial dosage optimisation of cyclosporine in Chinese paediatric patients undergoing allogeneic haematopoietic stem cell transplantation based on population pharmacokinetics: a retrospective study.BMJ paediatrics open · 2023Article
- Analysis of the variable factors affecting changes in the blood concentration of cyclosporine before and after transfusion of red blood cell concentrate.Journal of pharmaceutical health care and sciences · 2022Article
- Effects of intestinal microbiota on pharmacokinetics of cyclosporine a in rats.Frontiers in microbiology · 2022Article
- Population Pharmacokinetics of Cyclosporine in Chinese Pediatric Patients With Acquired Aplastic Anemia.Frontiers in pharmacology · 2022Article
- Factors Affecting Time-Varying Clearance of Cyclosporine in Adult Renal Transplant Recipients: A Population Pharmacokinetic Perspective.Pharmaceutical research · 2021Article
- Development of a Population Pharmacokinetic Model for Cyclosporine from Therapeutic Drug Monitoring Data.BioMed research international · 2021Article
- Pharmacokinetic and Pharmacodynamic Considerations in Relation to Calcineurin Usage in Elderly Kidney Transplant Recipients.Frontiers in pharmacology · 2021Review
- How to Handle Delayed or Missed Doses: A Population Pharmacokinetic Perspective.European journal of drug metabolism and pharmacokinetics · 2020Review
- Characterizing the pharmacokinetics and pharmacodynamics of immunosuppressant medicines and patient outcomes in elderly renal transplant patients.Translational andrology and urology · 2019Review
- Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?Journal of clinical pharmacology · 2019Review
- Pharmacokinetics of Toxin-Derived Peptide Drugs.Toxins · 2018Review
- Population pharmacokinetics of theophylline in adult Chinese patients with asthma and chronic obstructive pulmonary disease.International journal of clinical pharmacy · 2018Article
- External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients.British journal of clinical pharmacology · 2018Article
- Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center.European journal of clinical pharmacology · 2017Article
- Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.Pharmacotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of classical pharmacokinetic studies have been conducted in transplant patients. However, they suffer from some limitations, for example, (1) the study design was limited to intense blood sampling in small groups of patients during a certain posttransplant period, (2) patient factors were evaluated one at a time to identify their association with the pharmacokinetic parameters, and (3) mean pharmacokinetic parameters often cannot be precisely estimated due to large intraindividual variability. Population pharmacokinetics provides a potential means of addressing these limitations and is a powerful tool to evaluate the magnitude and consistency of drug exposure. Population pharmacokinetic studies of cyclosporine focused solely on developing limited sampling strategies and Bayesian estimators to estimate drug exposure, have been summarized before, and are, therefore, not a subject of this review. The major focus of this review is to describe factors (demographic factors, hepatic and gastrointestinal functions, drug-drug interactions, genetic polymorphisms of drug metabolizing enzymes and transporters) that have been identified to contribute to the large portion of observed variability in the pharmacokinetics of cyclosporine in transplant patients. This review summarizes and interprets the conclusions as well as the nonlinear mixed-effects modeling methodologies used in such studies. A highly diversified collection of structural models, variability models, and covariate submodels have been evaluated and validated using internal or external validation methods. This review also highlights areas where additional research is warranted to improve the models since a portion of model variability still remains unexplained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.